Abstracts Archive - Page 820 of 2607 - ACR Meeting Abstracts

Abstract Number: 1723 • ACR Convergence 2021
Factors Associated with Postpartum Flare in Women with Lupus
Anitha Ramu¹, Maedeh Veyseh¹, Brianna Lally², Shudan Wang³ and Anna Broder⁴, ¹Jacobi Medical Center/Albert Einstein College of Medicine, Bronx, NY, ²Albert Einstein College of Medicine, Bronx, NY, ³Albert Einstein College of Medicine/Montefiore Medical Center, New York, NY, ⁴Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY
Background/Purpose: Several prior studies have assessed disease activity in the setting of pregnancy and have shown that certain factors such as thrombocytopenia, systemic lupus erythematosus…
Abstract Number: 1724 • ACR Convergence 2021
More Than 50% of Women with Chronic Rheumatic Inflammatory Diseases Present an Unfavorable Pregnancy Outcome: A Descriptive Analysis of the National French Healthcare Database
Anna Molto¹, Barbara Roux², Diep Tran², Aya Ajrouche², nathalie costedoat-Chalumeau³, Elisabeth Elefant⁴, Vassilis Tsatsaris⁵, Jeanne Fresson⁶, Brigitte Bader-Meunier⁷, Bruno Fautrel⁸ and Florence Tubach², ¹Rheumatology department, Cochin hospital, APHP, Paris, France, ²CEPHEPI, APHP, Paris, France, ³Inserm DR Paris 5, Paris, France, ⁴Teratogenic agents refernce center (CRAT) , Hôpital Trousseau, APHP, Paris, France, ⁵Obstetrics Department, Port Royal Maternity, Cochin Hospital, APHP, Paris, France, ⁶CHU Nancy, Nancy, France, ⁷Pediatric Immuno-hematology, Necker Hospital, APHP, Paris, France, ⁸Pitié Salpêtrière Hospital, APHP, Sorbonne Université, Paris, France
Background/Purpose: Women with chronic rheumatic inflammatory diseases (CRID, i.e. rheumatoid arthritis (RA) or spondyloarthritis (SpA)) have been reported to have poorer pregnancy outcomes than the…
Abstract Number: 1725 • ACR Convergence 2021
Higher Prevalence of Aspirin Use with a Specific Educational Tool in SLE Pregnancies: Preliminary Results
Joo Young (Esther) Lee¹, Arielle Mendel², Isabelle Malhamé², Sasha Bernatsky¹ and Evelyne Vinet³, ¹McGill University, Montréal, QC, Canada, ²McGill University Health Centre, Montréal, QC, Canada, ³McGill University Health Centre, Mont Royal, QC, Canada
Background/Purpose: Pregnant women with SLE are at substantial risk of preeclampsia. Best international practice guidelines recommend aspirin (ASA) in this population, as it reduces preeclampsia…
Abstract Number: 1726 • ACR Convergence 2021
A Pregnancy Planning Quality Score to Assess a Systematic Intervention to Improve Pregnancy Planning for Women with SLE
Catherine Sims¹, Amanda Eudy¹, Jayanth Doss¹, Lisa Criscione-Schreiber², Kai Sun², Rebecca Sadun¹, Jennifer Rogers² and Megan Clowse³, ¹Duke University, Durham, NC, ²Duke University School of Medicine, Durham, NC, ³Duke University, Chapel Hill, NC
Background/Purpose: The safest pregnancies for women with SLE coincide with periods of disease quiescence maintained by pregnancy-compatible medications. In the US, Black women are more…
Abstract Number: 1727 • ACR Convergence 2021
Behcet’s Disease: A Meta-analysis of Pregnancy Outcomes
Leah Rooney¹, Aine Gorman², Matthew Turk³, Louise Moore⁴, Celine O'Brien⁵, Jared Bierbrier⁶, Anne Clohessy⁵, Eamonn Molloy⁷, Lorraine O Neill⁸, Fionnuala M. Mc Auliffe⁵ and Douglas Veale⁹, ¹St Vincent's University Hospital, Dublin, Ireland, ²St Vincents Hospital, Dublin, Ireland, ³St. Vincents University Hospital, Dublin, Ireland, ⁴Our Lady's Hospice and Care Services, Harold's Cross, Dublin 6W, Kinnegad, Ireland, ⁵Perinatal Research Centre, Obstetrics and Gynaecology, School of Medicine, University College Dublin and National Maternity Hospital, Dublin, Dublin, Ireland, ⁶McMaster University, Hamilton, ON, Canada, ⁷St Vincent's Healthcare Group, Dublin, Ireland, ⁸St. Vincent's Hospital, Dublin, Ireland, ⁹University College Dublin, Dublin, Ireland
Background/Purpose: Behcet’s disease is a systemic inflammatory disease which commonly presents with episodes of acute inflammation, oral and genital ulcers, uveitis and skin lesions. It…
Abstract Number: 1728 • ACR Convergence 2021
Takayasu’s Arteritis and Pregnancy: A Meta-analysis
Aine Gorman¹, Leah Rooney², Matthew Turk¹, Louise Moore³, Jared Bierbrier⁴, Celine O'Brien⁵, Anne Clohessy⁶, Eamonn Molloy⁷, Lorraine O Neill⁸, Fionnuala McAuliffe⁹ and Douglas Veale¹⁰, ¹St Vincents Hospital, Dublin, Ireland, ²St Vincent's University Hospital, Dublin, Ireland, ³Our Lady's Hospice and Care Services, Harold's Cross, Dublin 6W, Kinnegad, Ireland, ⁴McMaster University, Hamilton, ON, Canada, ⁵Perinatal Research Centre, Obstetrics and Gynaecology, School of Medicine, University College Dublin and National Maternity Hospital, Dublin, Dublin, Ireland, ⁶National Maternity Hopistal, Dublin, Ireland, ⁷St Vincent's Healthcare Group, Dublin, Ireland, ⁸St. Vincent's Hospital, Dublin, Ireland, ⁹National Maternity Hopsital Dublin, Dublin, Ireland, ¹⁰University College Dublin, Dublin, Ireland
Background/Purpose: Takayasu’s arteritis is a systemic autoimmune disease characterised by large vessel vasculitis. It usually affects women of childbearing age, with 90% of patients diagnosed…
Abstract Number: 1729 • ACR Convergence 2021
Predicting Adverse Pregnancy Outcomes in Women with Systemic Lupus Erythematosus (SLE) Using 2nd Trimester Estimated Glomerular Filtration Rate (eGFR)
Anika Lucas¹, Amanda Eudy¹, Michelle Petri², Rebecca Fischer-Betz³, Abeer Nabil⁴, Cecilia Nalli⁵, Laura Andreoli⁶, Angela Tincani⁷, Yair Molad⁸, Stephen Balevic¹ and Megan Clowse⁹, ¹Duke University, Durham, NC, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Uniklinik Dsseldorf, Dsseldorf, Germany, ⁴University of Cairo, Cairo, Egypt, ⁵ASST SPEDALI CIVILI DI BRESCIA, Brescia, Italy, ⁶University of Brescia, Brescia, Italy, ⁷ASST Spedali Civili-University of Brescia, Gussago, Italy, ⁸Rabin Medical Center, Beilinson Hospital, and Tel Aviv University, Petah-Tikva, Israel, ⁹Duke University, Chapel Hill, NC
Background/Purpose: Women with SLE are at increased risk for adverse maternal and fetal outcomes with increased odds of preeclampsia, hypertension, Cesarean and preterm deliveries, low…
Abstract Number: 1730 • ACR Convergence 2021
Disease Activity and Outcome in Pregnancies of Patients with SpA – Data from the German Pregnancy Register RHEKISS
Anja Weiß¹, Christina Bungartz¹, Jutta Richter², Susanna Späthling-Mestekemper³, Xenofon Baraliakos⁴, Peer Aries⁵, Rebecca Fischer-Betz⁶ and Anja Strangfeld⁷, ¹DRFZ, Berlin, Germany, ²Rheumatology and Hiller Research Unit, Heinrich-Heine-University Duesseldorf, Medical Faculty, Duesseldorf, Germany, ³Rheumapraxis München, München, Germany, ⁴Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ⁵Rheumatologie in Hamburg, Hamburg, Germany, ⁶Uniklinik Dsseldorf, Dsseldorf, Germany, ⁷Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany
Background/Purpose: SpA is a severe chronic inflammatory disease, which affects quality of life and functional status. It frequently occurs in women of childbearing age. Active…
Abstract Number: 1731 • ACR Convergence 2021
Construction and Validation of a Reproductive Health Questionnaire for Women with Rheumatic Diseases
Abraham Yair Lujano-Negrete¹, Luz Ferandanda Gutierrez-Leal², Luis Gerardo Espinosa-Banuelos³, Cassandra Michele Skinner-Taylor¹, Lorena Perez-Barbosa⁴, Ingris Peláez-Ballestas⁵, Eugenio Salvador Barriga-Maldonado⁶, Martha Cecilia Rodriguez-Ruiz¹, Sofía Jezzini-Martínez¹, Selene Maribel Delgado-Ayala¹, Jesus Cardenas-de La Garza⁴ and Dionicio Galarza-Delgado⁴, ¹Hospital Universitario Dr. José Eleuterio González, Monterrey, Mexico, ²Universidad Autónoma de Nuevo León, Monterrey, Mexico, ³Faculty of Medicine and University Hospital Dr. Jose Eleuterio Gonzalez, UANL, Monterrey, Mexico, ⁴Hospital Universitario "Dr Jose E. Gonzalez", Monterrey, Mexico, ⁵Hospital General de Mexico "Dr. Eduardo Liceaga", Mexico, Mexico, ⁶Hopsital Universitario Dr. José Eleuterio González, Monterrey, Mexico
Background/Purpose: Autoimmune rheumatic diseases (ARDs) commonly affect women of childbearing age. Active maternal disease in the months prior to conception increases the risk of flares…
Abstract Number: 1732 • ACR Convergence 2021
Effects of B Cell Activating Factors/B Lymphocyte Stimulator Inhibitors Added to Standard of Care on Infection in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Ruoning Ni¹, Jiayi Zheng² and Ruru Guo³, ¹Saint Agnes Healthcare, Baltimore, MD, ²Department of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China (People's Republic), ³Renji Hospital, Shanghai, China (People's Republic)
Background/Purpose: The efficacy of B cell activator factor/B lymphocyte stimulator inhibitors (BAFFi/BLySi) for systemic lupus erythematosus (SLE) has been proven in clinical trials. However, it…
Abstract Number: 1733 • ACR Convergence 2021
Classification of Patients with Systemic Lupus Erythematosus Enrolled in 2 Phase 3 Trials by EULAR/ACR 2019 Criteria
Martin Aringer¹, Ian N. Bruce², Richard Furie³, Eric Morand⁴, Emmanuelle Maho⁵, Catharina Lindholm⁶ and Raj Tummala⁷, ¹University Medical Center and Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany, ²University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ³Zucker School of Medicine at Hofstra/Northwell Health, Great Neck, NY, ⁴Monash University, Melbourne, Australia, ⁵BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ⁶BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ⁷BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD
Background/Purpose: The TULIP-1 and TULIP-2 trials of anifrolumab, an anti–type I IFN receptor mAb, enrolled autoantibody-positive (ANA, anti-dsDNA, and/or anti-Smith [anti-Sm]) patients, who fulfilled the…
Abstract Number: 1734 • ACR Convergence 2021
Efavaleukin Alfa, a Novel IL-2 Mutein, Selectively Expands Regulatory T Cells in Patients with SLE: Interim Results of a Phase 1b Multiple Ascending Dose Study
Nadia Tchao¹, Hamid Amouzadeh², Nandita Sarkar¹, Vincent Chow², Xuguang Hu¹, Mark Kroenke², Hui Wang², Rong Zhang², Kevin Gorski¹, Richard Furie³, Alan Kivitz⁴ and Stanley Cohen⁵, ¹Amgen Inc., South San Francisco, CA, ²Amgen Inc., Thousand Oaks, CA, ³Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ⁴Altoona Center for Clinical Research, Duncansville, PA, ⁵Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: Diminished IL-2 as well as both quantitative and qualitative abnormalities in regulatory T cells (Treg) are associated with autoimmune diseases including SLE. Efavaleukin alfa…
Abstract Number: 1735 • ACR Convergence 2021
Glucocorticoid Discontinuation in Patients with Systemic Lupus Erythematosus with Prior Severe Organ Manifestation
Takehiro Nakai¹, Futoshi Iwata¹, Genki Kidoguchi¹, Sho Fukui², Hiroki Ozawa¹, Satoshi Kawaai³, Yukihiko Ikeda¹, Ayako Koido⁴, Masei Suda⁵, Atsushi Nomura⁶, Hiromichi Tamaki¹, Kenichi YAMAGUCHI¹ and Masato Okada¹, ¹St. Luke's International Hospital, Tokyo, Japan, ²Immuno-Rheumatology Center, St. Luke’s International Hospital, and Center for clinical epidemiology, St. Luke’s International University, Tokyo, Japan, ³Immuno-Rheumatology Center, St. Luke’s International Hospital, Tokyo, Japan, Chuo-ku, Tokyo, Japan, ⁴St. Luke's International Hospital, Akashi-cho, Chuo-ku, Tokyo, Japan, ⁵Suwa Central Hospital, Nagano, Japan, ⁶St. Luke's International Hospital, Nagareyama, Japan
Background/Purpose: Most long-term damage in systemic lupus erythematosus (SLE) has been attributed to continuous glucocorticoid use; however, glucocorticoid discontinuation is occasionally associated with disease flare-ups.…
Abstract Number: 1736 • ACR Convergence 2021
Treatment of Lupus Nephritis with Belimumab Is Associated with Reduction in Urinary CD23
Emma Weeding¹, Andrea Fava², Chandra Mohan³, Daniel Goldman⁴ and Michelle Petri⁴, ¹Johns Hopkins Hospital, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³University of Houston, Houston, TX, ⁴Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Urine proteomic approaches have shown promise in identifying dynamic biological pathways in lupus nephritis (LN) which are not captured on renal histopathology or by…
Abstract Number: 1737 • ACR Convergence 2021
Reduction in Urinary CD163 Is Associated with Treatment Response in the Belimumab Lupus Nephritis Trial
Emma Weeding¹, Andrea Fava², Chandra Mohan³, Daniel Goldman⁴ and Michelle Petri⁴, ¹Johns Hopkins Hospital, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³University of Houston, Houston, TX, ⁴Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Urinary CD163 is a macrophage marker which correlates with histological activity index and response to treatment in lupus nephritis (LN), as evidenced by urine…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].